TOP TIERMARKET NEWSWIRE
Movers explained · 2026-08-06

Archived explainer. For the current picture see today's MDLN page.

Why Is MEDLINE INC A (MDLN) Stock Down Today?

By the Top Tier Newswire AI Desk · August 6, 2026 at 12:24 AM ET · reviewed against 11 wire stories

MEDLINE INC A (MDLN) is down -12.79% in the latest session. Our newswire has captured 11 stories on MDLN across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 52/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

MDLN stock fell 12.79% to $36.66 in Monday trading after the company cut its full-year adjusted EBITDA guidance during its Q2 2026 earnings call. The stock’s sharp decline came despite the company reporting a 12% year-over-year revenue increase to $7.7 billion and raising its organic sales outlook for 2026 to 9%-10%. The downward revision to EBITDA expectations and ongoing supply chain challenges weighed on investor sentiment.

What Happened

Medline reported Q2 2026 net sales of $7.7 billion, driven by strong demand in its medical-surgical product and supply-chain businesses. The company raised its full-year organic sales outlook but reduced its adjusted EBITDA guidance to $3.3 billion to $3.4 billion, citing the impact of the Tracy fire and U.S. tariffs. During the earnings call, CEO James Boyle highlighted the resilience of the business amid these headwinds but acknowledged the need for a more conservative EBITDA outlook. The stock’s decline followed this guidance cut, despite beating both revenue and earnings estimates.

What The Data Shows

MDLN has traded down 7.6% over the past eight sessions, from $39.70 to $36.67. Insider transactions show mixed signals, with 4 sell filings totaling $3.6 billion and 1 buy totaling $171,000 in the last 90 days. The stock currently trades within its 52-week range of $32.81 to $50.88, with a market cap of $34.2 billion and a P/E ratio of 36.8. Despite strong top-line growth, the company’s net margin remains at 3.3%, and the cut to EBITDA guidance has raised concerns about profitability.

What To Watch

The company’s updated EBITDA guidance and ongoing supply chain issues will be key to watch in the coming weeks. Investors should also monitor the breadth of coverage as the market reacts to the earnings report and any potential follow-up from analysts or institutional investors.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

MDLN by the numbers

Last: $36.66Session: -12.79%7 sessions: -13.06%Coverage: 11 stories / 6 sourcesAI sentiment: 52/100 (mixed)Mkt cap: $34.2BP/E: 36.852w: $32.81 to $50.88
MDLN · Aug 6 session (5-min) · -5.36% vs prior close · updated 8:44 PM ET
$34.37$35.58$36.79prev close $36.66$34.707:10 AM10:00 AM12:50 PM3:40 PM6:30 PM7:10 AM · $36.557:15 AM · $36.567:25 AM · $36.547:35 AM · $36.517:40 AM · $36.507:45 AM · $36.597:55 AM · $36.458:00 AM · $36.658:15 AM · $36.658:20 AM · $36.598:25 AM · $36.668:45 AM · $36.669:00 AM · $36.209:05 AM · $36.109:15 AM · $36.259:20 AM · $36.359:25 AM · $36.339:30 AM · $35.669:35 AM · $35.309:40 AM · $35.359:45 AM · $35.459:50 AM · $35.489:55 AM · $35.4510:00 AM · $35.6410:05 AM · $35.7710:10 AM · $35.7810:15 AM · $35.3310:20 AM · $35.4410:25 AM · $35.2810:30 AM · $35.2010:35 AM · $35.1310:40 AM · $35.0810:45 AM · $35.1610:50 AM · $35.2310:55 AM · $35.1611:00 AM · $35.2611:05 AM · $35.5211:10 AM · $35.3211:15 AM · $35.3011:20 AM · $35.2811:25 AM · $35.3711:30 AM · $35.4711:35 AM · $35.1711:40 AM · $35.2011:45 AM · $35.1911:50 AM · $35.1911:55 AM · $35.1312:00 PM · $35.1612:05 PM · $35.2812:10 PM · $35.2312:15 PM · $35.1912:20 PM · $35.1612:25 PM · $35.1312:30 PM · $35.1612:35 PM · $35.1012:40 PM · $35.1012:45 PM · $35.1012:50 PM · $35.1912:55 PM · $35.251:00 PM · $35.131:05 PM · $35.271:10 PM · $35.311:15 PM · $35.201:20 PM · $35.231:25 PM · $35.131:30 PM · $35.251:35 PM · $35.371:40 PM · $35.411:45 PM · $35.481:50 PM · $35.371:55 PM · $35.462:00 PM · $35.432:05 PM · $35.472:10 PM · $35.452:15 PM · $35.332:20 PM · $35.282:25 PM · $35.302:30 PM · $35.272:35 PM · $35.312:40 PM · $35.302:45 PM · $35.262:50 PM · $35.272:55 PM · $35.123:00 PM · $35.053:05 PM · $35.013:10 PM · $34.913:15 PM · $34.863:20 PM · $34.973:25 PM · $34.843:30 PM · $34.773:35 PM · $34.873:40 PM · $34.733:45 PM · $34.623:50 PM · $34.663:55 PM · $34.504:00 PM · $34.704:05 PM · $34.514:10 PM · $34.534:15 PM · $34.594:20 PM · $34.604:25 PM · $34.584:30 PM · $34.534:50 PM · $34.514:55 PM · $34.515:05 PM · $34.605:15 PM · $34.525:25 PM · $34.745:45 PM · $34.705:50 PM · $34.506:10 PM · $34.646:30 PM · $34.70
AI sentiment, last 36h · averaged over 11 stories · 52/100 neutral
AI sentiment 52/100 (neutral)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agopublishMarketChameleon · sentiment 67 · Medline's Second Quarter Highlights Strong Sales Growth, Adjusted EBITDA Expansion Despite Supply Headwinds August 5, 2026MarketChameleon · 67Medline's Second Quarter Highlights Strong Sales Growth, Adjusted EBITDA Expansion Despit…Seeking Alpha · sentiment 50 · Medline Inc. 2026 Q2 - Results - Earnings Call PresentationSeeking Alpha · 50Medline Inc. 2026 Q2 - Results - Earnings Call PresentationQuartz · sentiment 50 · MDLN Stock Price, News, Quote & History - qz.comQuartz · 50MDLN Stock Price, News, Quote & History - qz.comSeeking Alpha · sentiment 38 · Medline falls despite Q2 beat after cut to EBITDA outlookSeeking Alpha · 38Medline falls despite Q2 beat after cut to EBITDA outlookBusiness Insider · sentiment 38 · Kaplan Fox Urges Medline Inc. (MDLN) Investors to Contact the Firm About Possible Securities Law ViolationsBusiness Insider · 38Kaplan Fox Urges Medline Inc. (MDLN) Investors to Contact the Firm About Possible Securit…Yahoo Finance · sentiment 56 · Medline Q2 Earnings Call HighlightsYahoo Finance · 56Medline Q2 Earnings Call HighlightsSeeking Alpha · sentiment 50 · Medline Inc. (MDLN) Q2 2026 Earnings Call TranscriptSeeking Alpha · 50Medline Inc. (MDLN) Q2 2026 Earnings Call TranscriptSeeking Alpha · sentiment 56 · Medline raises 2026 organic sales outlook to 9%-10% while lowering adjusted EBITDA to $3.3B-$3.4BSeeking Alpha · 56Medline raises 2026 organic sales outlook to 9%-10% while lowering adjusted EBITDA to $3.…
5d agoSeeking AlphaBULLISH 56Earnings

Medline raises 2026 organic sales outlook to 9%-10% while lowering adjusted EBITDA to $3.3B-$3.4B

Medline (MDLN) Q2 2026 earnings call recap: 12% sales growth, raised organic sales outlook, lower EBITDA guide after Tracy fire & tariffs.

5d agoSeeking AlphaNEUTRAL 50Earnings

Medline Inc. (MDLN) Q2 2026 Earnings Call Transcript

Medline Inc. (MDLN) Q2 2026 Earnings Call August 5, 2026 9:30 AM EDTCompany ParticipantsKaren King - Global Head Investor RelationsJames Boyle - CEO &...

5d agoYahoo FinanceBULLISH 56Earnings

Medline Q2 Earnings Call Highlights

Medline (NASDAQ:MDLN) reported second-quarter 2026 net sales growth of 12% to $7.7 billion, supported by demand across its medical-surgical product and supply-chain businesses, while raising its full-year organic sales outlook. The company also lowered its adjusted EBITDA guidance, citing operationa

5d agoBusiness InsiderBEARISH 38General

Kaplan Fox Urges Medline Inc. (MDLN) Investors to Contact the Firm About Possible Securities Law Violations

New York, New York--(Newsfile Corp. - August 5, 2026) - Kaplan Fox Kilsheimer LLP is investigating...

5d agoSeeking AlphaBEARISH 38Earnings

Medline falls despite Q2 beat after cut to EBITDA outlook

Medline (MDLN) stock falls after cutting full-year adjusted EBITDA guidance despite Q2 beats and higher sales outlook. Read more here.

5d agoQuartzNEUTRAL 50General

MDLN Stock Price, News, Quote & History - qz.com

5d agoSeeking AlphaNEUTRAL 50Earnings

Medline Inc. 2026 Q2 - Results - Earnings Call Presentation

2026-08-05. The following slide deck was published by Medline Inc.

5d agoMarketChameleonBULLISH 67Earnings

Medline's Second Quarter Highlights Strong Sales Growth, Adjusted EBITDA Expansion Despite Supply Headwinds August 5, 2026

Medline reported robust top-line growth and resilient operational results in the second quarter and first half of 2026, overcoming significant one-time headwinds and updating its full-year guidance. The company maintained strong Adjusted EBITDA margin gains, delivered healthy free cash flow, and signaled ongoing confidence in demand, even as headline net income was impacted by extraordinary items like a major distribution center fire.

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on MDLN: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier MDLN move explainers: 2026-08-06 · 2026-08-05